#United States #Burlington, Massachusetts #Innovate #BrioHealth #BrioVAD

BrioHealth Solutions Reaches a Significant Milestone

On December 22, 2025, BrioHealth Solutions proudly announced a standout achievement: the 100th enrollment in the INNOVATE Trial for the BrioVAD® System, a state-of-the-art Left Ventricular Assist Device (LVAD). This principled endeavor aims to address critical unmet needs in the care of patients suffering from advanced heart failure, offering them innovative solutions to manage their condition effectively.

The BrioVAD® System is engineered to enhance blood circulation, elevate patient comfort, and mitigate the risks of complications, with a strong focus on the overall well-being of patients. The device is designed to ameliorate the adverse impacts typically associated with advanced heart failure treatments, thereby granting patients the precious gift of time to cherish life and its moments.

"The enrollment of our 100th participant underscores our organization’s commitment and the dedication of our clinical trial partners to innovate in heart care," stated Dr. Chen Chen, CEO of BrioHealth Solutions. He emphasized the significance of this milestone not only in expanding treatment options but also in the transformative potential the BrioVAD® System holds for patients grappling with advanced heart disease.

Initiated in late 2024, the INNOVATE Trial serves as a pivotal national research study that brings together preeminent heart centers across the nation. It aims to evaluate the effectiveness of this innovative mechanical heart pump, specifically for patients whose hearts cannot sufficiently circulate blood independently. This vital trial examines the BrioVAD® System with the goal of creating more reliable, long-lasting devices that not only enhance longevity but also enrich the quality of life.

Dr. Francis D. Pagani, the National Principal Investigator of the INNOVATE Trial and Professor of Cardiac Surgery at the University of Michigan Medical School, commented, "With each successful implantation, we advance our understanding of the BrioVAD® System's full capabilities, ultimately expanding treatment options for patients facing advanced heart failure. We feel optimistic about the journey so far and remain resolute in our commitment to shape the future of heart-failure care."

As the trial progresses, it continues to recruit participants and gather essential data that will inform future therapeutic approaches and potentially broaden access for patients in need. Such advancements are crucial in the relentless effort to improve heart failure treatment outcomes.

BrioHealth Solutions firmly believes that the BrioVAD® System signifies a major leap forward in the landscape of heart failure therapies. The company strives to restore, prolong, and enhance the lives of patients across the globe by forging collaborations with healthcare providers and elevating the benchmarks of medical technology.

Conclusion

If you seek more comprehensive information about the INNOVATE Trial or the BrioVAD® System, please visit The INNOVATE Trial. It's important to note that the BrioVAD® System is considered an investigational device, with its usage limited by Federal (US) law to the context of this trial. BrioHealth Solutions is steadfast in their commitment to pioneering solutions that truly make a difference in patients' lives.